Ozurdex in the treatment of diabetic macular edema. When to prescribe?

doi:https://doi.org/10.17116/oftalma2019135041121

Close metadata

Recommended articles:

Diverse manifestations of orbital pseudotumor in a six-year-old child (case study). Russian Annals of Ophthalmology. 2024;(5):106-111

Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies. Russian Annals of Ophthalmology. 2024;(5):154-161

Indirect comparison of anti-angiogenic agents in the treatment of diabetic macular edema. Russian Annals of Ophthalmology. 2024;(6):69-79

Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema. Russian Annals of Ophthalmology. 2024;(6):100-106

Angiographic parameters of the retina after various methods of membrane peeling in the treatment of diabetic maculopathy. Russian Annals of Ophthalmology. 2025;(1):37-44

The effects of intraoperative use of angiogenesis inhibitors on outcomes and complication rates in the surgical treatment of proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2025;(2):44-50

Abstract:

Retinal damage in diabetes is known to manifest in two main ways: diabetic retinopathy and diabetic macular edema. The most effective anti-inflammatory drugs today are glucocorticoids, a classic representative of which is dexamethasone. Two things that should be considered by ophthalmologists in the therapy of macular edema are the switching point to dexamethasone implant when the effectiveness of anti-vasoproliferative drugs is unsatisfactory, and the identification of the main predictors of diabetic macular edema that make glucocorticoids the drugs of first choice. The data from real clinical practice was used to develop the indications for intravitreal administration of a glucocorticoid as the therapy of first choice for diabetic macular edema. Glucocorticoids are prescribed to patients diagnosed with diabetic macular edema who has a history of acute cerebrovascular events, myocardial infarction or other cardiovascular and cerebrovascular diseases, as well as patients with a very high risk of a vascular catastrophe. Intravitreal glucocorticoids can be prescribed to patients who cannot follow the schedule of frequent visits and/or are not able to visit the hospital during the first 6 months after the administration of the drug. Considering the local character of its ophthalmic action, the method can be recommended for treating patients with pseudophakic eyes, persistent diabetic macular edema, or patients who underwent vitrectomy.

Keywords:

diabetic macular edema

ozurdex

glucocorticoids

macula

Close metadata

References:

Fayzrakhmanov RR. Morphofunctional peculiarities of retina central area at wet froms of age-related macular degeneration. Tochka zreniya. Vostok—Zapad. 2016;2:115-118. (In Russ.)
Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Survey of Ophthalmology. 1984;28(supp):452-461.
Fayzrakhmanov RR, Budzinskaya MV. Macular pigments in retinal degenerative processes. Vestnik oftal’mologii. 2018;134(5-1):135-140. (In Russ.) https://doi.org/10.17116/oftalma2018134051135
Fayzrakhmanov RR, Zaynetdinov AF, Salavatova VF. Structure of vitreomacular interface in retinal pathology. Tochka zreniya. Vostok—Zapad. 2017;2:82-85. (In Russ.)
Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA, Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. READ-2 Study Group. Ophthalmology. 2010;117(11):2146-2151. https://doi.org/10.1016/j.ophtha.2010.08.016
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-2405. https://doi.org/10.2337/dc10-0493
Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Archives of Ophthalmology. 2012;130(8):972-979. https://doi.org/10.1001/archophthalmol.2012.393
Zainullin RM, Fayzrakhmanov RR, Gilyazova II. Morphological and functional characteristics of the central zone of the retina in patients with diabetic macular edema. Vestnik Orenburgskogo gosudarstvennogo universiteta. 2015;12(187):76-80. (In Russ.)
Gonzales VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, Ma J, Ho AC, Patel V, Whitcup SM, Dugel PU. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. American Journal of Ophthalmology. 2016;172:72-79.
Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in Immunopathology. 2008;30(2):65-84. https://doi.org/10.1007/s00281-008-0111-x
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914. https://doi.org/10.1016/j.ophtha.2014.04.024
Cui QN, Stewart JM. Intravitreal dexamethasone implant (Ozurdex) as primary treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science. 2014;55:1780. https://doi.org/10.1167/iovs.13-12375
Ye He, Xin-jun Ren, Bo-jie Hu, Wai-Ching Lam, Xiao-rong Li A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmology. 2018;18:121. https://doi.org/10.1186/s12886-018-0779-1
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW, Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022
Fayzrakhmanov RR. Regimens of administration of anti-VEGF-drugs in the treatment of neovascular age-related macular degeneration. Vestnik oftal’mologii. 2018;6:105-113. (In Russ.) https://doi.org/10.17116/oftalma2018134061107
Kodjikian L, Bellocq D, Mathis T. Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. BioMed Research International. 2018;8289253. https://doi.org/10.1155/2018/8289253
Singer MA, Dugel PU, Fine HF, Capone A, Maltman J, Real-World Assessment of Dexamethasone Intravitreal Implant in DME: Findings of the Prospective, Multicenter REINFORCE Study. Ophthalmic Surgery, Lasers and Imaging Retina. 2018;49(6):425-435. https://doi.org/10.3928/23258160-20180601-07
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222. https://doi.org/10.1159/000458539
Edge R, McGarvey DJ, Truscott TG. The carotenoids as anti-oxidants — a review. Journal of Photochemistry and Photobiology. B, Biology. 1997;41(3):189-200. https://doi.org/10.1016/s1011-1344(97)00092-4
Ma L, Dou HL, Wu YQ, Huang YM, Huang YB, Xu XR, Zou ZY, Lin XM. Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis. British Journal of Nutrition. 2012;107(3):350-359. https://doi.org/10.1017/s0007114511004260
Neelam K, Hogg RE, Stevenson MR, Johnston E, Anderson R, Beatty S, Chakravarthy U. Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiology. 2008;15(6):389-401. https://doi.org/10.1080/09286580802154275
Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, Fobker M, Pauleikhoff D. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental luteinand zeaxanthin: The LUNA study. Experimental Eye Research. 2007;84(4):718-728. https://doi.org/10.1016/j.exer.2006.12.010
Age-Related Eye Disease Study Group. A randomized, placebo controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Archives of Ophthalmology. 2001;119(10):1417-1436. https://doi.org/10.1001/archopht.126.9.1251
Ho L, van Leeuwen R, Witteman JC, van Duijn CM, Uitterlinden AG, Hofman A, de Jong PT, Vingerling JR, Klaver CC. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ω-3 fatty acids: the Rotterdam study. Archives of Ophthalmology. 2011;129(6):758-766. https://doi.org/10.1001/archophthalmol.2011.141
Cangemi FE. TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmology. 2007;26(7):3. https://doi.org/10.1186/1471-2415-7-3